These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 11961260)
1. Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. RamÃrez JC; Tapia E; Esteban M J Gen Virol; 2002 May; 83(Pt 5):1059-1067. PubMed ID: 11961260 [TBL] [Abstract][Full Text] [Related]
2. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750 [TBL] [Abstract][Full Text] [Related]
3. Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies. Crickard L; Babas T; Seth S; Silvera P; Koriazova L; Crotty S PLoS One; 2012; 7(11):e48706. PubMed ID: 23133652 [TBL] [Abstract][Full Text] [Related]
4. Selection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library. Shin YW; Chang KH; Hong GW; Yeo SG; Jee Y; Kim JH; Oh MD; Cho DH; Kim SH J Microbiol Biotechnol; 2019 Apr; 29(4):651-657. PubMed ID: 30856707 [TBL] [Abstract][Full Text] [Related]
5. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. McCausland MM; Benhnia MR; Crickard L; Laudenslager J; Granger SW; Tahara T; Kubo R; Koriazova L; Kato S; Crotty S Antivir Ther; 2010; 15(4):661-75. PubMed ID: 20587859 [TBL] [Abstract][Full Text] [Related]
7. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. Reading PC; Symons JA; Smith GL J Immunol; 2003 Feb; 170(3):1435-42. PubMed ID: 12538705 [TBL] [Abstract][Full Text] [Related]
8. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Chen Z; Earl P; Americo J; Damon I; Smith SK; Zhou YH; Yu F; Sebrell A; Emerson S; Cohen G; Eisenberg RJ; Svitel J; Schuck P; Satterfield W; Moss B; Purcell R Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1882-7. PubMed ID: 16436502 [TBL] [Abstract][Full Text] [Related]
17. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. Hall RA; Brand TN; Lobigs M; Sangster MY; Howard MJ; Mackenzie JS J Gen Virol; 1996 Jun; 77 ( Pt 6)():1287-94. PubMed ID: 8683218 [TBL] [Abstract][Full Text] [Related]
18. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280 [TBL] [Abstract][Full Text] [Related]
19. Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies. Czerny CP; Mahnel H J Gen Virol; 1990 Oct; 71 ( Pt 10)():2341-52. PubMed ID: 1700065 [TBL] [Abstract][Full Text] [Related]